Wyss InstituteImmuno-Materials – Wyss Institute

TIB: Tolerance Inducing Biomaterials for Regulatory T Cells

Jessica Leff — Mon, 06 Jul 2026 17:38:18 +0000

Tissue regeneration following injuries and degenerative processes benefits greatly from the activity of regulatory T cells (Tregs) that help balance the immune system, which senses, regulates, and helps restore tissue environments following injury and in disease. In fact, immune therapies using Tregs have shown first promise in treating a wider variety of diseases. However…

Source

The Wyss Institute’s 2026-2027 Validation Projects

Jessica Leff — Mon, 06 Jul 2026 14:00:41 +0000

Each year, the Wyss Institute’s Validation Project program identifies technologies that are ready to move beyond the discovery and into the validation phase. Through dedicated funding, technical resources, business development support, market research, and engagement with clinicians, investors, industry experts, and key opinion leaders, the program helps research teams de-risk high-impact…

Source

Materializing safe, on-demand living therapeutics

Jessica Leff — Thu, 14 May 2026 17:55:55 +0000

By Benjamin Boettner (BOSTON) — Patient recovery from many debilitating conditions and diseases could be sped up significantly and be more effective if drugs and therapeutic molecules were delivered right to where they are needed in the body, over the entire regenerative process, and in doses finely tuned to therapeutic needs. An intriguing way to achieve this is the use of implantable…

Source

20-ish Questions with David J. Mooney

Jessica Leff — Fri, 19 Dec 2025 13:41:58 +0000

20-ish Questions shows a different side of Wyss Institute faculty, touching on aspects of their personal life, hobbies, interests, as well as their research. This round follows David J. Mooney, a Founding Core Faculty member and Lead of the Immuno-Materials platform at the Wyss Institute. He is also the Robert P. Pinkas Family Professor of Bioengineering at the Harvard John A.

Source

First-in-human clinical trial of personalized, biomaterial-based cancer vaccine demonstrates feasibility, safety, and immune activation

Jessica Leff — Wed, 10 Dec 2025 17:11:46 +0000

By Benjamin Boettner (BOSTON) — The first-in-human phase I clinical trial assessing the feasibility and safety of WDVAX, an immunostimulatory biomaterial-based cancer vaccine, in a cohort of 21 patients with stage 4 metastatic melanoma, was concluded with positive outcomes that encourage future vaccine developments and trials to test them in combination with immune checkpoint inhibitor…

Source

Biomaterial vaccines to make implanted orthopedic devices safer

Jessica Leff — Mon, 03 Nov 2025 19:55:42 +0000

By Benjamin Boettner (BOSTON) — Patients with implanted medical devices like orthopedic joint replacements, pacemakers, and artificial heart valves run a small but significant risk that these devices get infected with bacterial pathogens. This starts them on a burdensome path requiring “redo” (revision) surgeries, prolonged antibiotic treatments, or in severe cases amputation.

Source

Charles Park named 2025 STAT Wunderkind

Seth Kroll — Fri, 17 Oct 2025 18:57:05 +0000

By Seth Kroll (BOSTON) — The Wyss Institute is proud to announce that Charles Park, Ph.D., a postdoctoral researcher in the Wyss’ Immuno-Materials Platform with Wyss Core Faculty member Samir Mitagotri, Ph.D., has been named a 2025 STAT Wunderkind by STAT News. The STAT Wunderkinds are annual awards that honor early-career scientists whose creativity and perseverance are helping to reshape…

Source

The Wyss Institute’s 2025-2026 Validation Projects

Jessica Leff — Thu, 14 Aug 2025 15:00:53 +0000

Throughout recent years, the Wyss’ Validation Project mechanism has proven to be a highly valuable instrument for selecting and kick-starting projects with early potential for positive impact on healthcare and the environment. Reaching deep into areas with major unmet needs across the diverse Grand Challenges laid out by the Institute, the newly selected projects are driven by multi-talented teams…

Source

David Mooney on the Mission to Save Lives Through Cancer Research

Jessica Leff — Fri, 25 Jul 2025 17:02:46 +0000

David Mooney, Core Faculty member of the Wyss Institute and Robert Pinkas Family Professor of Bioengineering in the Harvard School of Engineering and Applied Sciences, discusses training immune cells to recognize and destroy cancer mutations. While current immunotherapies create nearly miraculous cures for some patients, they only work for certain cancers and a fraction of those affected. Mooney’…

Source

20-ish Questions with Samir Mitragotri

Jessica Leff — Thu, 08 May 2025 14:52:36 +0000

20-ish Questions shows a different side of Wyss Institute faculty, touching on aspects of their personal life, hobbies, interests, as well as their research. This round follows Samir Mitragotri, a Core Faculty member of the Wyss Institute as well as a Professor of Bioengineering and Biologically Inspired Engineering at the Harvard John A. Paulson School of Engineering and Applied Sciences.

Source